Why the study?
Does edoxaban improve efficacy and safety compared to apixaban, dabigatran, and rivaroxaban in patients with atrial fibrillation?
Population
Patients with atrial fibrillation (AF) requiring stroke prevention
Comparison
Edoxaban vs Apixaban, dabigatran etexilate, and rivaroxaban
Design
Meta-analysis
Authors
Loading...
Apixaban may reduce bleeding versus high-dose edoxaban in AF; extends indirect comparisons but leaves direct RCTs open.
Does edoxaban improve efficacy and safety compared to apixaban, dabigatran, and rivaroxaban in patients with atrial fibrillation?
Indirect comparisons of NOACs for stroke prevention in AF reveal differential efficacy and bleeding risks, supporting individualized anticoagulant selection based on patient clinical profiles.
Larsen et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: